Collaborative Arrangements - Platform Technology Transfer and License Agreement (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	May 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Apr. 30, 2020	Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer, liability		$ 5,045,000		$ 5,045,000			$ 2,044,000
Revenue recognized		14,967,000	$ 12,319,000	29,637,000	$ 27,901,000
Novartis [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Term of collaborative research and development agreement	23 months
Contract with customer, liability	$ 5,000,000.0
Revenue recognized		$ 900,000	$ 0	$ 3,700,000	$ 0
Novartis [Member] | Royalty [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Term of collaborative research and development agreement	23 months
Novartis [Member] | Computer Equipment and Software [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent annual receivable increase	$ 8,000,000.0
Novartis [Member] | Milestone One [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent receivable						$ 4,000,000.0
Novartis [Member] | Milestone Two [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent receivable	$ 5,000,000.0